At ASN Kidney Week 2025, Glucagon-like peptide-1 (GLP-1) receptor agonists moved firmly into the nephrology spotlight, with ...
Grassmuno – also known as Grass MATA MPL – is also the first subcutaneous grass pollen allergy immunotherapy to be cleared by ...
Enhertu is already approved as a second-line or later treatment for HER2-positive breast cancer, along with other indications ...
Benger will take over from Roberts – who was named CEO in 2021 and announced her decision to step down in the summer – on ...
The rise of NP/PA influence is not a passing trend; it is a structural realignment of US healthcare. These clinicians are the ...
The FDA has delivered a Commissioner's National Priority Voucher (CNPV) to Johnson & Johnson for a combination regimen based ...
The clinical trial industry is at a critical juncture where traditional methods are proving insufficient for managing today’s ...
In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Benedict Cross, Chief Technology Officer at PhoreMost, a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback